CLX

Business profile & competitive position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. It manufactures and markets a mix of consumer and professional products under brands including Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, Burt’s Bees, Purell, CloroxPro, and Clorox Healthcare. Its fiscal 2026 net sales were $6.7 billion, generated by roughly 9,200 employees operating in about 25 countries and selling into approximately 95 markets. In April 2026 it closed the GOJO Industries acquisition, expanding its health and hygiene footprint and adding to its business-to-business exposure.

The company’s net margin of 8.7% is respectable but not exceptional for a branded consumer-products business. Its P/E of 16.9 is in mid-pack valuation territory, while its beta of 0.54 fits the defensive label, meaning the stock has tended to move less than the overall market. The real head-scratcher is the ROE figure of negative 1,893.5%. ROE equals net income divided by shareholders’ equity, so a figure that extreme can only come from very low or negative common equity on the balance sheet. With that kind of book-value structure, ROE is not a useful signal of competitive strength here; investors should focus on margins, cash generation and brand durability instead of treating that ROE as a moat metric.

Financial posture

Clorox’s market cap is $9.8 billion and it trades at a P/E of 16.9. The net margin is 8.7%, and the beta is 0.54, confirming the low-volatility, defensive classification. Because the stated ROE is negative 1,893.5%, traditional return-on-equity analysis is distorted; the number reflects accounting equity mechanics rather than a clean read on how effectively management is deploying shareholder capital.

Other financial dynamics from the 10-K are more telling. Diluted EPS fell 26% in fiscal 2026, organic sales and earnings declined, and results were hurt by macro headwinds plus the timing of an ERP rollout that had pulled some sales into fiscal 2025. Customer concentration is real: Walmart accounted for 26% of fiscal 2026 consolidated net sales, and the top five customers represented about half of all sales. That concentration gives large retailers meaningful bargaining leverage and creates volume risk if any major relationship changes.

Strategic priorities & outlook

Clorox’s most recent 10-K describes a company focused on four strategic choices under its IGNITE strategy: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.

Operationally, management is pushing three main engines. First, it is completing and optimizing a new enterprise resource planning system alongside a broader digital transformation, with the goal of generating long-term efficiencies across supply chain, digital commerce, innovation and brand building. Second, it is investing in strong brands, strategic digital capabilities and a streamlined operating model to build resilience and deliver consistent, profitable growth. Third, it is advancing health and hygiene expansion and portfolio optimization, including integrating the newly acquired GOJO business and growing in professional and institutional markets.

These priorities matter because they explain the current earnings pressure: ERP transitions are disruptive, and GOJO integration costs will weigh on near-term results even if they are intended to create a larger B2B platform over time.

Macro & geopolitical exposure

As a Consumer Defensive/Household & Personal Products company, Clorox is exposed to the usual staples-industry forces. Raw-material inflation is a constant risk: resins, plastics, pulp, packaging materials, vegetable oils and chemicals all feed into cleaning, bags, charcoal and personal-care products. Freight, warehousing and labor costs also move the cost structure. Because products are sold in roughly 95 markets, currency fluctuations affect repatriated revenue and reported earnings.

Regulatory and policy exposure is inherent to the category. The Environmental Protection Agency regulates disinfectant claims, chemical formulations and labeling; the Food and Drug Administration and Federal Trade Commission touch personal-care and health-oriented products; and state-level rules around packaging, sustainability and chemical disclosure continue to tighten. Trade policy can affect both the cost of imported inputs and the competitiveness of exports. In addition, the sector faces private-label competition, especially when inflation pushes consumers to trade down, and concentrated retail customers can demand pricing concessions.

Recent developments

Recent headlines show a mix of product momentum and investor caution. On September 28, 2026, PR Newswire reported that Clorox announced the official launch of Clorox Purell ProCare™. On the same day, 247WallSt published “Clorox Just Raised Its Dividend Again. Can Earnings Keep Up?” and Seeking Alpha ran “Clorox: The 6% Yield & Bargain Valuation Can’t Fix A Slow Recovery.” A few days earlier, on September 24, 2026, Seeking Alpha published “Clorox’s Selloff May Not Be Over Yet (Rating Downgrade).” Taken together, the news flow highlights new product activity and income appeal, while the analyst community is questioning whether the fundamental recovery can support the current valuation and dividend trajectory.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox beat earnings expectations six times, for a 75% beat rate, with an average earnings surprise of 9.6%. The average five-day price change after those reports was a gain of 1.67%, classified as an upward drift.

The most recent quarters, however, illustrate how noisy that drift can be. For the August 3, 2026 report, the company earned $1.66 versus an estimate of $1.64, a 1.2% beat, and the stock rose 6.52% the next day and 9.61% over the following five days. The prior quarter, April 30, 2026, produced a 5.8% beat on EPS of $1.64 versus $1.55, yet the stock fell 9.67% the next day and 4.49% over five days. On February 3, 2026, the company missed by 2.8% with $1.39 versus $1.43, but the stock still gained 2.43% the next day and 5.63% over five days. The November 3, 2025 quarter saw a 3.9% beat on $0.85 versus $0.818, yet the next-day move was only 1.17% and the five-day drift was negative 4.08%.

The lesson is that the historical beat rate and average positive drift are useful statistical context, not a prediction. The next scheduled report is November 3, 2026 after the close, with a consensus EPS estimate of $1.11.

For a deeper view beyond the headline numbers and recent news flow, readers should examine the full institutional verdict and sell-side research consensus on Clorox.